Memantina Synthon

Memantine Hydrochloride, the active ingredient in Memantina Synthon, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients. GNH USA supplies Memantina Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride acts on glutamatergic neurotransmission and is used in the management of Alzheimer’s disease. - Alzheimer’s disease (moderate to severe): improves cognition, functional abilities and global clinical status in adults with moderate to severe disease.

Memantine Hydrochloride may be associated with several adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired. - Nausea: upset stomach or urge to vomit. - Cough: dry or productive cough.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Hallucinations: visual or auditory perceptual disturbances. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm. - Liver enzyme elevation: abnormal liver function tests. - Psychosis: delusional thoughts or severe confusion.

Before initiating therapy with Memantine Hydrochloride, consider the following precautions. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic disease: monitor liver enzymes and use with caution. - History of seizures: evaluate risk versus benefit. - Concomitant CNS depressants: watch for additive sedation. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Memantine Hydrochloride can interact with several medications.

Major Interactions (Avoid): - Amantadine: may reduce memantine efficacy and increase side‑effects. - Ketamine: additive NMDA antagonism can potentiate neuropsychiatric effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment. - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Proton pump inhibitors: may alter memantine absorption. - High‑dose vitamin D: potential for hypercalcemia. - Diuretics: monitor electrolytes and renal function.